CAP-02
Regimen
- Experimental
- camrelizumab + apatinib
Population
Unresectable locally advanced, recurrent, or metastatic ESCC progressed after or intolerant to first-line chemotherapy
Key finding
Confirmed ORR 34.6% (95% CI 22.0-49.1); grade>=3 TRAE 44% (mostly transaminase elevation); no treatment-related deaths
Source: PMID 34998471